SCHEMBL3407795

SCHEMBL3407795

O=C(O)CCCCN(C(=O)Oc1ccc(Cl)cc1)c1ccc2nc(S)sc2n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 1/20 0.35
TMPRSS15 P98073 3/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
MAPK1 P28482 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
LTB4R Q15722 1/20 0.32
LTA4H P09960 1/20 0.31
CA2 P00918 1/20 0.31
DRD2 P14416 1/20 0.31
DRD3 P35462 1/20 0.31
PDE2A O00408 1/20 0.31
PDE3B Q13370 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403090 0.89 TMPRSS15 (0.33) TMPRSS15ALDH1A1
SCHEMBL3405767 0.88 PPARG (0.37) PPARDTMPRSS15MAPTSMN1; SMN2ALDH1A1
SCHEMBL3405727 0.88 MMP2 (0.35) TMPRSS15MAPT
SCHEMBL3404311 0.87 CA2 (0.37) TMPRSS15CA2
SCHEMBL3402006 0.86 KMT2A (0.32) PPARDTMPRSS15KMT2A
SCHEMBL3404320 0.85 TMPRSS15 (0.31) TMPRSS15HDAC6
SCHEMBL3408841 0.84 KMT2A (0.36) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3405763 0.83 TMPRSS15 (0.37) PPARDTMPRSS15ALDH1A1TP53LTA4H
SCHEMBL3403697 0.83 TMPRSS15 (0.32) TMPRSS15PDE2APDE3BPDE3A
SCHEMBL2864220 0.83 PPARD (0.40) PPARDTMPRSS15MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1370260-B1 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI PHARMACEUTICAL CO LTD (JP) 2010-11-24 EP claimed
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-05-13 US claimed
EP-1370260-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-12-17 EP claimed
WO-2002066035-A2 AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-08-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092503-A1 Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators ME1, ME3, ME2 PPARD 1235/4885TMPRSS15 959/4885MAPT 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.